Eurofins Discovery

The growing adoption of generative artificial intelligence (AI) in the drug discovery process promises to revolutionize the identification of novel drugs and to shorten development time.  Efficiently translate AI-mediated discoveries into safe & impactful drugs with our comprehensive Integrated Drug Discovery (IDD) solutions. ✔ Extensive Assay Portfolio: An industry-leading breadth of target-based and translational assays, with new panels on helicases, SH2 domains, and obesity targets. ✔ Experience: With the IDD team, you work directly with scientists with years of discovery experience. They collaboratively guide the program, design necessary assays & services, and tap into scientific subject matter experts. ✔ Innovative AI Solutions: Complement your approaches with Eurofins’ DiscoveryAI & access cutting-edge tools. Join the companies using Eurofins Discovery as their trusted partner for end-to-end drug development services, from target validation to IND-enabling studies. https://lnkd.in/ge3DiVdQ

Did you miss our recent webinar, “Accelerating Drug Discovery with Synthetic Chemistry Advances”? Or did you attend and want to revisit key insights? Great news—the recording is now available! Presented by Matthew Horwitz, this webinar highlights the latest approaches in drug discovery, with a focus on small molecules and emerging modalities like proteolysis-targeting chimeras (PROTACs) and antibody-drug conjugates (ADCs). Access the webinar recording: https://lnkd.in/dUH6Pxec At Eurofins Discovery, we cover the entire drug discovery workflow with over 10,000 off-the-shelf assays, from chemistry capabilities to biology services. Learn more and connect with our experts: https://lnkd.in/ehhRvvxc #DrugDiscovery #Chemistry #SyntheticChemistry 

🚀 Reach Next-Level Drug Discovery with DiscoveryAI SAFIRE! Ready to transform your drug discovery process? Our cutting-edge SAFIRE technology, powered by AI and high-quality Eurofins Discovery data, is here to revolutionize how you approach drug development. 🔗 Watch the Video: Get an inside look at how SAFIRE can elevate your drug discovery process. https://lnkd.in/g-vFtfmU Start harnessing the power of SAFIRE today and make informed decisions with confidence! #DrugDiscovery #AI #Pharma #Innovation #MachineLearning

🚀 Exciting developments at Eurofins Discovery Taiwan! The team recently had the pleasure of hosting Dr. Alastair J. King, Head of Biology at Eurofins Discovery, from the St. Charles site in the U.S. 💡 Dr. King shared valuable insights, including a successful case of using BioMAP® and OncoPanel® in oncology drug discovery, providing the Taiwan team with key takeaways. His strategies inspired new ideas on aligning our unique service portfolio to serve clients better globally. 🌍 Cross-site visits like this are invaluable, strengthening our teamwork and fueling innovation. We look forward to more collaboration across the Eurofins Discovery network! #Eurofins #EurofinsAsia #EurofinsDiscovery #Oncopanel #BioMAP #Collaboration

Exciting news! We are expanding our Oncology portfolio. In our ongoing quest for innovation, coupled with always meeting our clients' needs as effectively as possible, we are investing in our oncology capabilities. We recently expanded our SH2scan™ platform, adding new SH2 domain assays for proteins in a variety of classes including E3 ligases, adaptor proteins, phosphatases, GTPase-activating proteins, and phospholipases for a comprehensive SH2MAX panel that brings this “undruggable” target class within therapeutic reach. This panel uses the same proprietary binding assay technology as our KINOMEscan platform. Download our flyer now to explore new approaches in drug discovery targeting SH2 domains and see our remaining 2024 screening slots to check if your molecules are active - only 3 slots left before the end of this year. Download: https://lnkd.in/gQv5_-cP #Eurofins #Oncology #DrugDiscovery

Attending the Pistoia Alliance 2024 Philadelphia conference, November 12 - 13? Please join our Head of Biology, Alastair King, Ph.D. for his talk: “How non animal models can contribute to your R&D sustainability objectives” This dynamic session will explore the transformative power of in vitro assays and in silico predictive analysis effectiveness replacing traditional animal models with ethical, efficient, and scientifically advanced alternatives. Date: November 13th Time: 2:15 pm (EST) Breakout session 3 (Sustainability Driven R&D)

🚀 We’re Hiring: Zone / Cloud Infrastructure IT Manager! 🚀 If you’re a strategic IT professional with a passion for innovative tech solutions, this is your opportunity to lead our regional zone IT infrastructure and drive our cloud footprint to new heights! Join us to shape the future of Drug Discovery at Eurofins. Ready to make an impact? Explore the details and apply here: https://lnkd.in/gysyZffr #Eurofins #Hiring #CareerOpportunity #ITJobs #JoinOurTeam

Did you miss our recent webinar, “Rapid Functional Cell-Based Activity Profiling of Multi-Receptor Targeted Anti-Obesity Therapies” presented by Luke Oostdyk and hosted by Drug Target Review? No worries—it’s now available to watch on demand! 📽️ Watch (or rewatch) the full webinar here: https://lnkd.in/ggyErJG9 At Eurofins Discovery, our team of experts has deep experience in addressing major metabolic disorders. Take advantage of our specialized platform for anti-obesity compound characterization! Learn more about our Metabolic Disorder Capabilities: https://lnkd.in/gfaSpfBT Need further assistance? Fill out this form and one of our experts will get in touch: https://lnkd.in/gJBg9Ftd #DrugDiscovery #AntiObesity

How do you comprehensively characterize therapeutic antibodies? Don’t miss out on this case study demonstrating our molecular approach to thoroughly characterize trastuzumab, a humanized monoclonal antibody targeted against the ErbB2 protein and approved to treat HER2-positive breast cancer. This case study highlights guidelines from regulatory agencies regarding monoclonal antibodies. It shows how the Eurofins Discovery approach provides you with the robust, reliable, and quality data you need to make confident decisions that will progress your program into preclinical development. Download now to see how Eurofins Discovery’s safety screening and profiling vigilance can save you time and resources in your biotherapeutics program. Get more details: https://lnkd.in/gnNk_7VQ #biotherapeutics #trastuzumab #drugdiscovery #eurofinsdiscovery

🚨 Join Eurofins Discovery at AusBiotech 2024! 🚨 We’re excited to invite you to AusBiotech 2024, taking place October 30th - November 1st in Melbourne. Don't miss the opportunity to hear from Alastair King, Ph.D., Head of Biology at Eurofins Discovery, as he participates in a panel discussion on "Translational Biology Platforms as Animal Model Alternatives." 📍 Visit us at Booth #25: 🔬 Our Integrated Drug Discovery Services offer instant access to 700+ discovery scientists empowered by state-of-the-art technologies coupled to Chemistry expertise and the industry's largest portfolio of 12,000+ validated assays. We provide your team with dedicated support, target class expertise, care of your intellectual property, and therapeutic focus so you can deliver candidates with the best chance to be first, or best, in class. 🤖 We offer AI solutions that complement our ADME services and virtual screening to make your hit finding program even more efficient. 🤝 Explore potential collaboration opportunities with our experts.  We look forward to seeing you there! Feel free to reach out if you're attending or would like more information. #AusBiotech2024 #DrugDiscovery #TranslationalBiology #LifeSciences #Eurofins #DiscoveryAI